Researchers determine epigenetic origin of docetaxel-resistant breast cancer

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have published a study in Molecular Cancer Research in which they identify methylation patterns associated with different subtypes of breast cancer, and a subclassification of the group of "triple negatives," a breast cancer type typically associated with poor prognosis. In addition, they identified changes in DNA methylation associated with the response to docetaxel, a common therapy. The research was led by Dr. Eva González-Suárez, head of the IDIBELL Transformation and Metastasis research group.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/researchers-determine-epigenetic-origin-of-docetaxel-resistant-breast-cancer